Medicine :: Biomarkers in Late Stage Clinical Trials: Applications, opportunities and activities of leading players | ArticleBiz.

com

The pharmaceuticals and biotechnology sectors are currently facing increasing time and cost the business of clinical trials in drug discovery. The cost of creating a new drug can reach $2 billion; many studies, regulatory approval and subsequent launch will take up to decade. Biomarkers decrease the attrition rate recently stage many studies by assessing drug potential regarding efficacy and toxicity at the first stages with the clinical development. Thus, biomarkers significantly increase productivity, lower the fee and duration with the clinical trial, and help researchers complete drug development process at a faster pace. This report reviews various biomarker technologies and therapy area applications. Market drivers and restraints are viewed within the context of biomarker activity of leading innovator companies as well as contract research organizations. Key top features of this report The report analyzes revenues of late stage biomarker technology and services in North America, Europe, Asia and rest in the world. Provides key market drivers and restraints of the biomarker market. Covers microarrays, immunoassay, LC/MS and GC/MS, flow cytometry, imaging, PCR and services Provides patent analysis when it comes to competitors and geography. Scope with this report Understand and evaluate the growth potential of emerging technologies. Understand biomarker activity in clinical trials of leading market players. Gain know-how about the relative importance with the biomarker late stage numerous studies technologies within the next 5yrs for investment opportunities. Learn which therapy areas leading market players in the late stage biomarker numerous studies market. Determine the collaborations and partnerships of the major market players. Key Market Issues

The pharmaceutical and biotech sectors are currently facing increasing duration and price the business of numerous studies in drug discovery. Funding from government sources for example the National Institutes of Health (NIH) has not yet increased significantly throughout the last number of years. Late stage failures less difficult more costly than early ones. The rising interest in better safety data has put a considerable amount of regulatory and economic pressure on pharmaceutical companies. The current average approval rate of cancer drugs is really as low as 5%, even though the development period can reach fifteen years. More than 50% of clinical trials fail in Phase III because of host of reasons, greater disease complexity, stiffer clinical endpoints, and also the inability from the data to prove drug effectiveness. Key findings from this report The biomarkers in late stage many studies information mill largest in North American and European region, with Europe having the second largest market. North America constitutes the main market share while using immunoassay, flow cytometry and GC/MS and LC/MS having high market growth. Caprion proteomics, Applied BioSystems, BG Medicine, Covance, Eli Lilly, Pfizer and Astra Zeneca are some in the major companies engaged in collaborative partnerships inside past 3 years. A number of market players have formed strategic alliances for the development and sharing of technology for biomarker applications inside late stage numerous studies. Pharmaceutical companies are focusing mainly on cancer biomarkers to use in late stage (Phase III and IV) clinical trials. Key questions answered How is the biomarker late stage numerous studies market segmented and what will growth be to 2014? What are the most important technologies that have emerged such as microarrays, PCR, LC/MS and GC/MS? In which areas will be the companies focusing while forming strategic alliances with other industrial players? What is the competitive landscape and what is the strategic focus of innovator companies, CROs and biomarker specialists? What applications are pharmaceutical companies centering on while conducting late stage biomarker many studies?

Table of Contents Biomarkers in Late Stage Clinical Trials Executive summary 12 Market dynamics 12 Biomarker activity at leading pharma companies 13 Applications of biomarkers in clinical trials 13 Biomarker market for late stage clinical trials by tools and services 14 Company profiles 15 Chapter 1 Market dynamics 18 Chapter 2 Biomarker activity at leading pharma companies 40 Chapter 3 Applications of biomarkers in clinical trials 62 Chapter 4 Biomarker industry for late stage many studies by tools and services 80 Appendix 147